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Abstract Recent evidence suggests that ageing-related
diseases could result in an accelerated loss of self-
renewal capability of adult stem cells, normally involved
in replacing damaged cellular elements. In previous
works, we highlighted that a specific treatment, named
tissue optimization-regenerative (TO-RGN), of radio-
electric asymmetric conveyer (REAC) technology,
influenced gene expression profiles controlling stem cell
differentiation and pluripotency of human skin-derived
fibroblasts in vitro. The purpose of the present work was
to verify whether TO-RGN may also be effective in
counteracting the expression of the senescence marker
beta-galactosidase and of senescence-associated gene
expression patterning, engaged during prolonged culture
of human adipose-derived stem cells (hADSCs).
Following TO-RGN exposure, we observed a significant
downregulation in beta-galactosidase staining and in the
expression of the senescence mediator genes p16INK4,
ARF, p53, and p21CIP1. Moreover, differently formed
untreated cells, TO-RGN-exposed hADSCs maintained
their typical fibroblast-like morphology and exhibited a
multilineage potential even at late passages, as shown by
the remarkable preservation of commitment to osteo-
genic, adipogenic, chondrogenic, and vasculogenic
fates, both at morphologic and gene expression levels.
In conclusion, our study highlights a positive effect of
TO-RGN in counteracting degenerative senescence pro-
cesses in vitro.
Keywords Ageing . Anti-aging . Adipose-derived
stem cells . Geroconversion . REAC
Introduction
Ageing is a complex process characterized by loss of
tissue homeostasis and a progressive and widespread
decline in physical performance and cognitive func-
tions of the whole organism. Tissue integrity is
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physiologically maintained by resident stem cells,
which are able to replace damaged or lost cells.
Recent advances in stem cell research have proposed
an intriguing hypothesis concerning ageing: exhaus-
tion of stem cells may be a primary cause of ageing
(Sharpless and DePinho 2007; Sahin and Depinho
2010). Adult stem cells can be found in tissues
throughout the human body, including bone marrow
and fat. These cells although pluripotent, contrary to
embryonic stem cells, have a differentiation capability
limited to the retention of tissue homeostasis, by re-
placing damaged or dying cells throughout the human
life span (Bryder et al. 2006; Morrison and Kimble
2006). They exhibit specific physiological and bio-
chemical properties. First of all, mesenchymal stem
cells (MSCs) can differentiate into distinctive end-
stage cell types, required to form many mesenchymal
tissues, including bone, cartilage, muscle, bone mar-
row stroma, tendons/ligaments, fat, dermis, and other
connective tissues. Moreover, MSCs participate to the
injury response by a so-called “homing capacity,”
through which they can localize into the damaged
tissue and secrete a wide range of bioactive molecules
with “trophic activity” (Wright et al. 2001). However,
the regenerative capability of MSCs is subjected to a
series of biochemical changes that occurs during age-
ing, and deeply affect their self-renewal potential. It
seems that the expression of specific mediators of
senescence, may act through tumor suppressing and
growth arrest mechanisms, playing a very important
role in aging. Among these, the cyclin-dependent ki-
nase inhibitors, p16INK4a and ARF, significantly ac-
cumulates with normal aging in rodents and humans in
cells of a variety of tissues (Alcorta et al. 1996;
Rheinwald et al. 2002; Randle et al. 2001; Chkhotua
et al. 2003; Melk et al. 2004; Nielsen et al. 1999;
Zindy et al. 1997). The activation of p16INK4a and
ARF induces p53 pathways, including the expression
of the cyclin-dependent kinase inhibitors p21CIP1,
leading to cell cycle arrest and regenerative defects
(Bringold and Serrano 2000).
Moreover, during ageing, cells undergo senescence-
associated changes which include cellular widening,
higher lysosome biogenesis, and expression of a beta-
galactosidase that has a pH optimum of 6 (senescence-
associated β-galactosidase or SA-β-Gal). It is now gen-
erally accepted that stem cells, which undergo acceler-
ated cellular senescence, can contribute to age-related
diseases (Vijg and Campisi 2008). We have previously
shown that a treatment, named tissue optimization-
regenerative (TO-RGN), of radio-electric asymmetric
conveyer (REAC) technology (Rinaldi and Fontani
2000, 2001), significantly influenced the differentiation
capability of mouse embryonic stem cells (Maioli et al.
2011), as well as pluripotency and plasticity of human
skin-derived fibroblasts (Maioli et al. 2012a). In the
present study, we investigated whether TO-RGN may
be able to counteract the expression of SA-β-Gal and
modulate the transcription of a number of senescence
mediator genes, recruited throughout prolonged cultur-
ing of human, adipose-derived stem cells (hADSCs).
Material and methods
Ethics statement
According to the policy approved by the local ethical
committee of the University of Bologna (title of ap-
proved project: “Assessment of mesenchymal stem
cells in human adipose tissue,” code number
013/2010/O/Tess, date of approval from the ethical
committee: 16 February 2010), all tissue samples were
obtained after informed consent. All participants,
according to the consent procedure approved by the
ethical committee, provided their written consent spe-
cifically dedicated to the harvesting of their abdominal
fat (50–100 mL of lipoaspirate).
Radio-electric asymmetric conveyer technology
for therapeutic use
REAC is an innovative patented technology
(WO2002004069) (Rinaldi and Fontani 2000, 2001)
for bio-stimulation and/or bio-enhancement tech-
niques that induces weak radio-electric currents in
the tissues, to induce a cell reprogramming activity
(Maioli et al. 2012a). The model used in this study
(B.E.N.E Bio enhancer–Neuro enhancer, ASMED,
Florence, Italy) is specific for regenerative treat-
ments. Recently, using TO-RGN treatment proto-
col, the REAC technology has demonstrated the
chance to drive stem cell pluripotency and differ-
entiation (Maioli et al . 2011), and a cell
reprogramming activity (Maioli et al. 2012a).
The physical underpinnings of REAC technology
are the following: upon interaction of two oscillators,
namely two electromagnetic fields, a resultant
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oscillatory pattern may be generated, in actual fact a
resultant current and magnetic field. Exploitation of
the REAC technology implies that among the
interacting oscillators, one is represented by the oscil-
lating electromagnetic field generated by cells or by
the entire organism and the other by a weaker electro-
magnetic field produced by the REAC apparatus itself.
Upon the establishment of such a dual system, a
resultant electromagnetic field is generated that in-
duces the cells or the organism to respond in an
autologous fashion with self-generated radio-electric
microcurrents, likely ensuing from an array of cellular
ionic fluxes. By the aid of REAC technology, these
autologous radio-electric currents can be asymmetri-
cally focused with a conveyer probe to produce a
therapeutic effect on a given selected area of the entire
organism or elicit transcriptional and signaling events
that drive reprogramming and differentiating decisions
in isolated (stem) cell cultures. The unique features of
the REAC technology thus provide a complete cus-
tomization and non-invasiveness of treatments, in the
absence of side effects, due to the nature of the treat-
ment itself. On the whole, these achievements pave the
way to novel perspectives at the level of both basic
science and clinical settings that are currently
approached according to specific validated protocols.
REAC tissue optimization: regenerative treatment
(TO-RGN)
The REAC TO-RGN consists of a sequence of radio
frequency burst of 250 ms with an off interval of 2.5 s.
The REAC apparatus, was placed into a CO2 incuba-
tor, was set at a frequency of 2.4 GHz, and its con-
veyer electrodes were immersed into the culture
medium of hADSCs. REAC radiated power is about
2 mW, electric field E=0.4 V/m, Magnetic field
1 mA/m, specific absorption rate (SAR) 0.128 μW/g;
the density of radio-electric current flowing in the
culture medium during the REAC single radio fre-
quency burst is J=30 μA/cm2.
Isolation and culture of hADSCs
Human subcutaneous adipose tissue samples were
obtained from lipoaspiration/liposuction procedures
by 50-year-old female donors (n=14). Their mean
BMI was 25.47 and their mean age was 49.57. After
washing, lipoaspirates were digested with 0.2 %
collagenase A type I solution (Sigma-Aldrich), under
gentle agitation for 45 min at 37 °C, and centrifuged at
2,000×g for 10 min to separate the stromal vascular
fraction from adipocytes. If necessary, the hADSC
fraction was treated with red blood cell lysis buffer
for 5 min at 37 °C, and then centrifuged again. The
supernatant was discarded, and the cell pellet was
resuspended and seeded in culture flasks in DMEM-
low glucose (Lonza) supplemented with 20 % heat
inactivated FBS, 1 % penicillin-streptomycin, 2 mM
L-glutamine, and incubated at 37 °C in a humidified
atmosphere with 5 % CO2. When the cultures were
near confluence, the cells were detached by treatment
with trypsin and seeded in six-well tissue culture
plates (3×103 cells/cm2) at the appropriate passages.
The REAC apparatus, was placed into a CO2 incuba-
tor, was set at 2.4 GHz, and its conveyer electrodes
were immersed for 4, 8, or 12 h into the culture
medium of hADSCs at passages 5, 10, 15, 20, 25,
and 30. The widths and lengths of at least ten individ-
ual controls and TO-RGN-treated hADSCs at different
passages were recorded using an Olympus IX71
fluorescence-inverted microscope at 100× magnifica-
tion oil immersion. Images were analyzed with the
software “ANALYSIS,” and these data were averaged
to produce a single average measurement of cell
length and width.
Characterization of hADSCs by flow cytometry
analysis
ADSCs obtained from adipose tissues were harvested
by treatment with 0.08 % trypsin-EDTA and incubated
with 1 μg/106 cells FITC-conjugated antibodies for
40 min at 4 °C in the dark. The antibodies used were:
SH2, SH3, SH4, anti-CD166, anti-CD14, anti-CD34,
anti-CD44, and anti-CD45. After washing, cells were
analyzed on a flow cytometer (FACSCalibur, Becton
Dickinson, San Jose, CA, USA) by collecting 10,000
events and the data analyzed using the Cell Quest
Software (Becton Dickinson). hADSCs were positive-
ly stained with SH2, which identifies an epitope of
endoglin (CD105), were recognized by the SH3 and
SH4 antibodies, which identify epitopes on culture-
expanded stromal cells and bind CD73, a molecule
involved in B cell activation. hADSCs were also pos-
itive for CD29, the beta-subunit of an integrin family
behaving as the major receptor for extracellular matrix
molecules, CD166, an hMSC marker not found in
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hematopoietic precursors, and were uniformly positive
for the CD44 hyaluronate receptor. Conversely, anti-
gen profiles were negative for the hematopoietic
markers CD14 and CD34 and the leukocyte common
antigen CD45.
Senescence associated β-galactosidase staining
SA-β-Gal staining was performed using a “Senescence-
associated β-Galactosidase Staining Kit” (Cell
Signalling). Briefly, hADSCs cultured at passages 5,
10, 15, 20, 25, and 30 were exposed for 12 h in the
absence or presence of REAC in six-well plates (3×103
cells per well). Subsequently, cells were fixed with
fixative solution and then processed according to the
manufacturer’s instructions. All the experiments were
repeated three times, and one of the representative re-
sults was shown. The cells were then photographed
under an inverted microscope at 100× magnification
for qualitative detection of SA-β-Gal activity. The num-
ber of positive (blue) and negative cells was counted in
five random fields under the microscope (at 200× mag-
nification and bright field illumination), and the percent-
age of SA-β-Gal-positive cells was calculated as the
number of positive cells divided by the total number of
counted cells.
Assessment of cell viability
hADSCs cultured at passages 5, 10, 15, 20, 25, and 30
were exposed for 12 h in the absence or presence of
REAC in six-well plates (6×103 cells per well). Cell
viability was determined by the trypan blue dye ex-
clusion test (Life Technologies). Both attached and
floating cells were harvested and counted by using
countess automated cell counter.
Adipogenesis, osteogenesis, and vasculogenesis
in culture
To test cell capability to differentiate toward mesen-
chymal phenotypes, hADSCs at passages 5 and 30,
exposed or not to REAC for 12 h, were committed
toward adipogenic, osteogenic, and vascular pheno-
types. To induce adipogenic differentiation, 10×
103 cells/cm2 were cultured in an adipogenesis induc-
tion medium (Millipore) composed by DMEM-low
glucose, supplemented with 10 % FBS, 0.5 mM
isobutyl-methylxanthine, 200 μM indomethacin,
1 μM dexamethasone, and 10 μg/mL insulin in a 24-
well microplate, replacing the medium every 2–3 days.
At day 7 and 10 of differentiation, total RNA was
extracted and the expression of the two adipogenic
Fig. 1 TO-RGN exposure enhances hADSC viability. After plating
(6×103 cells/well), cells were left untreated or treated with TO-RGN
for 12 h and counted to estimate cell growth. The number of vital
cells assed by trypan blue dye exclusion was significantly higher in
REAC-exposed samples than in untreated controls. (Asterisk) sig-
nificantly different from untreated cells (mean ± SD, n=4) (P<0.05)
12 AGE (2014) 36:9–20
markers, adipocyte Protein 2 (aP2) and peroxisome
proliferator-activated receptor γ (PPARγ), was evalu-
ated by real-time PCR. After 2–3 weeks of culture, the
cells were fixed in 10 % formalin and stained with fresh
oil red-O solution. To induce osteogenic differentiation,
10×103 cells/cm2 were plated in a 24-well microplate in
DMEM-low glucose supplemented with 10 % FBS,
10 mM β-glycerophosphate, 0.2 mM ascorbic acid, and
10 nM dexamethasone (Mesenchymal Stem Cell
Osteogenesis Kit, Millipore), and cultured for 3–4 weeks,
replacing the medium every 2–3 days. To demonstrate
osteogenic differentiation, the cultures were fixed and
stained with Alizarin Red solution, and total RNA was
extracted to evaluate specific osteogenic differentiation
related genes, as Runt-related transcription factor 2
(RUNX-2) and bone sialoprotein (BSP). Concerning an-
giogenesis, as previously shown the expression of
vasculogenic genes, including vascular endothelial
growth factor (VEGF), and von Willebrand factor
(vWF) genes can be remarkably enhanced following the
exposure of hADSCs to a mixture of natural molecules
including hyaluronan (H), butyric (B), and retinoic acids
Fig. 2 REAC TO-RGN counteracts senescence-associated β-
galactosidase activity. hADSCs at passages 5 (panels A), 15
(panels B), 20 (panels C), 25 (panels D), and 30 (panels E)
were plated in six-well plates (3×103 cells per well). After
overnight culture for attachment, cells were cultured in the
absence or presence of REAC for 12 h. Then, hADSCs were
processed for SA-β-Gal assessment and photographed under a
microscope at 100× magnification. SA-β-Gal activity was
measured after culturing for 12 h with (blue line) or without
TO-RGN (red line) treatment (panel F). The number of positive
(blue staining) and negative cells was counted in five random
fields under the microscope (at 200× magnification and bright
field illumination), and the percentage of SA-β-Gal-positive
cells was calculated as the number of positive cells divided by
total number of counted cells. (Asterik) significantly different
from the untreated cells (mean ± SD, n=3) (P<0.05)
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(R) (Bianchi et al. 2012; Cavallari et al. 2012). Here, we
use a 24–72-h exposure to a mixture containing H
(2 mg/mL), B (5 mM), and R (1 μM) to induce the
expression of the vasculogenic gene VEGF, and the
vascular marker vWF factor. Analysis of capillary-like
tube formation was performed using Cultrex® Basement
Membrane Extract (BME, Thema). Capillary-like struc-
tures were observed after 12–24 h at regular time
intervals, and photographed using an inverted optical
microscope equipped with a digital sight camera (Nikon).
Gene expression
Total RNAwas isolated from hADSCs exposed or not to
TO-RGN for 4, 8, or 12 h, using Trizol reagent
according to the manufacturer's instruction (Life
Fig. 3 Effect of REAC TO-RGN on p16INK4a gene expression.
hADSCs at passages 5, 10, 15, 20, 25, and 30, reaching 80 %
confluence, were exposed for 4, 8, or 12 h in the absence or presence
of REAC. The amount of p16INK4a mRNA from control (white
bars) and TO-RGN treated (blue bars) cells was normalized to
HPRT1 and was plotted as fold change relative to the mRNA expres-
sion at passage 5 (time 0), defined as 1. (Asterisk) significantly
different from the untreated cells (mean ± S.E.; n=6) (P<0.05)
Fig. 4 Effect of REACTO-RGNonARFgene expression. hADSCs
at passages 5, 10, 15, 20, 25, and 30, reaching 80% confluence, were
exposed for 4, 8, or 12 h in the absence or presence of REAC. The
amount of ARF mRNA from control (white bars) and TO-RGN-
treated (red bars) cells was normalized to HPRT1 and was plotted as
fold change relative to the mRNA expression at passage 5 (time 0),
defined as 1. (Asterisk) significantly different from the untreated cells
(mean ± S.E.; n=6) (P<0.05)
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Technologies). Total RNA was also isolated from con-
trol and REAC-treated hADSCs (time of exposure 12 h)
at passages 5° and 30° committed toward adipogenic (at
days 7 and 10 of culture), osteogenic (at day 7 of
culture) and vascular (at day 7 of culture) phenotypes.
Total RNAwas dissolved in RNAase-free water, and for
RT-PCR, cDNA was synthesized in a 50-μL reaction
volume with 1 μg of total RNA and MuMLV reverse
transcriptase (RT) according to the manufacturer's in-
struction (Invitrogen). Quantitative real-time PCR was
performed using an iCycler Thermal Cycler (Bio-Rad).
Two microliters of cDNA were amplified in 50-μL re-
actions using Platinum Supermix UDG (Invitrogen),
200 nM of each primer, 10 nM fluorescein (BioRad),
and Sybr Green. After an initial denaturation step at
94 °C for 10 min, temperature cycling was initiated.
Fig. 5 Effect of REAC TO-RGN on p53 gene expression. hADSCs
at passages 5, 10, 15, 20, 25, and 30, reaching 80% confluence, were
exposed for 4, 8, or 12 h in the absence or presence of REAC. The
amount of p53 mRNA from control (white bars) and TO-RGN-
treated (purple bars) cells was normalized to HPRT1 and was plotted
as fold change relative to the mRNA expression at passage 5 (time 0),
defined as 1. (Asterisk) significantly different from the untreated cells
(mean ± S.E.; n=6) (P<0.05)
Fig. 6 Effect of REAC TO-RGN on p21 gene expression. hADSCs
at passages 5, 10, 15, 20, 25, and 30, reaching 80% confluence, were
exposed for 4, 8, or 12 h in the absence or presence of REAC. The
amount of p21 mRNA from control (white bars) and TO-RGN-
treated (green bars) cells was normalized to HPRT1 and was plotted
as fold change relative to the mRNA expression at passage 5 (time 0),
defined as 1. (Asterisk) significantly different from the untreated cells
(mean ± S.E.; n=6) (P<0.05)
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Each cycle consisted of 94 °C for 15 s, 55–59 °C for
30 s, and 60 °C for 30 s, the fluorescence being read at
the end of this step. To evaluate the quality of product of
real-time PCR assays, melting curve analysis was
performed after each assay. Relative expression was
determined using the “delta-CT method”with hypoxan-
thine phosphoribosyltransferase 1 (HPRT1) as a refer-
ence gene. The mRNA levels of control and TO-RGN
exposed hADSCs were expressed as fold of change
(2 −ΔΔCt), relative to the mRNA levels of the enzyme
evaluated in hADSCs at passage 5 when cells reached
80 % confluence before starting TO-RGN treatment
(time 0).
Specific primers for p16, p19, p21, p53, and
HPRT1 used in this study were from Invitrogen and
previously described (Maioli et al. 2011; Bea et al.
2001; Isenmann et al. 2007; Vandesompele et al. 2002;
Maioli et al. 2012b). Specific primers used for
adipogenic commitment were: aP2 forward 5′-
AGACATTCTACGGGCAGCAC-3′ and reverse 5′-
TCATTTTCCCACTCCAGCCC-3′, and PPARγ for-
ward 5′-GCAAACCCCTATTCCATGCTG-3′ and re-
verse GCAGGCTCCACTTTGATTGC.
Specific primers for osteogenic commitment, as
core binding factor alpha 1 (CBFA1/RUNX-2), and
BSP, were previously described (Polini et al. 2011).
Specific primers for angiogenesis as VEGF were
previously described (Ventura et al. 2007) while




The statistical analysis of the data was performed by
using the Statistical Package for Social Science, ver-
sion 13. For this study, nonparametric statistical tests
were used: Friedman and Wilcoxon-signed rank test.
The first was used to detect differences in treatments
across multiple test attempts; the second was used to
evaluate, in the same group, the differences (delta CT)
between the data collected over a period of observa-
tion related to the treated and nontreated cells. Test,
and all results P<0.05 have been considered statisti-
cally significant.
Results
TO-RGN treatment remarkably influenced cell viabil-
ity, as shown by its ability to significantly enhance the
number of vital cells as compared to untreated controls
(Fig. 1). Figure 2 (panels A–F) represents SA-β-Gal
staining in hADSCs cultured in the absence or pres-
ence of TO-RGN throughout an observation period of
90 days. It is evident that the number of SA-β-Gal-
stained cells (blue) was already significantly reduced
at passage 5 in TO-RGN-treated hADSCs. This be-
havior became more evident with the passage of time
in culture, with a progressive increment in the differ-
ence of positively SA-β-Gal-stained cells between
REAC exposed and unexposed cells (Fig. 2, panels
A–F). Moreover, in the last passages not only the number
of SA-β-Gal positive cells, but also the intensity of the
SA-β-Gal staining was remarkably reduced following
TO-RGN exposure. Separate analysis of cellular mor-
phology revealed that unlike control cells, which devel-
oped an ailing morphology in the last passages, TO-
RGN-exposed cells still exhibited their classical
fibroblast-like morphology, even at passages 25 and 30.
In particular, length to width ratio was higher in REAC-
treated cells, ranging between 8.078±0.6 and 5.043±
0.55 (mean ± SD from ten separate REAC-exposed cell
cultures at passages 25 and 30, respectively), as compared
to untreated cells, ranging between 5.025±0.35 and
3.993±0.33 (mean ± SD from ten separate untreated
control cell cultures at passages 25 and 30, respectively).
Figures 3, 4, 5, and 6 show respectively the gene
expression of p16INK4, ARF, p53 and p21 in
hADSCs at passages 5, 10, 15, 20, 25, and 30 treated,
or not, with TO-RGN for 4, 8, or 12 h. The expression
Fig. 7 Effect of REAC on multi-lineage differentiation and
gene expression patterning in hADSCs cultured at different
passages in the absence or presence of REAC. At passages 5,
or 30, hADSCs were treated for 12 h in the absence or presence
of REAC, and processed as described under “Material and
methods” for: a adipogenic differentiation, revealed by Oil
Red-O staining for neutral lipids (100× magnification), and by
the gene expression of aP2 and PPARγ; b osteogenic differen-
tiation, evidenced by the formation of mineralized matrix, as
shown by Alizarin Red staining (100× magnification), and by
the gene expression of BSP and RUNX2. c Vasculogenic dif-
ferentiation was assessed by capillary tube-like formation in
semisolid medium after 24 h of treatment in the absence or
presence of REAC (100×, original magnification), and by the
gene expression analysis of VEGF and vWF. (White bars)
untreated controls; (black bars) REAC-treated cells. Immuno-
histochemistry is representative of four separate experiments.
For gene expression analyses, total RNA was extracted after
7 days in culture. (Asterisk) Significantly different from
untreated control cells (mean ± S.E.; n=6)
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of p16, ARF p53, and p21 increased throughout the
investigated culturing passages (Figs. 3, 4, 5, and 6) in
control hADSCs, while it was significantly less de-
tectable in TO-RGN-exposed cells. Moreover, this ef-
fect of TO-RGN was particularly evident at passages 25
and 30. hADSCs at passages 5 and 30 treated with TO-
RGN exhibited also a higher differentiation capability
toward adipogenic, osteogenic, and vasculogenic line-
ages, as compared to control cells (Fig. 7, panels a–c).
Adipogenic differentiation showed multiple adipocytic
multivacuolar cells, the size increasing with the time of
induction (Fig. 7, panels a). Moreover, hADSCs at pas-
sages 30 exposed to TO-RGN also expressed higher
levels of the adipogenic-associated genes, aP2 and
PPARγ, as compared to control cells (Fig. 7, panels a).
Osteogenic differentiation was revealed as early as the
first week of induction bymorphological changes and, at
the end of the induction period, by the formation of
mineralized matrix and calcium deposits as demonstrat-
ed by Alizarin Red staining (Fig. 7, panels b). Gene
expression analysis of osteogenic-associated genes,
RUNX2 and BSP revealed higher expression levels of
both factors in TO-RGN-treated hADSCs, as compared
to control cells (Fig. 7, panels b). Vasculogenic differen-
tiation was assessed in control or TO-RGN-treated
hADSCs cultured for 24 h in semisolid medium, at
passages 5 and 30 (Fig. 7, panels c). The TO-RGN
treatment increased both the number of capillary-like
tubes and their branching assembly, as compared with
unexposed controls (Fig. 7, panels c). The higher
vasculogenic differentiation capability of TO-RGN-
treated hADSCs was also inferred by their enhanced
expression of the vasculogenic gene VEGF and of the
vascular specific gene vWF, with respect to untreated
cells (Fig. 7, panels c).
Discussion
It has been demonstrated that the regenerative ca-
pability of stem cells isolated from elder patients
is lower as compared to younger subjects
(Lapasset et al. 2011). This age-related alteration,
together with a reduced self-renewal potential of adult
stem cells, can also be observed during long-term culture
in vitro (Chambers and Goodell 2007). Therefore, iden-
tifying a strategy that could revert the molecular cues
controlling stem cell senescence in vitro may represent
an important progress for future cell therapy
development. Indeed, advances in the perspective of a
regenerative medicine were recently obtained by revers-
ing the age-altered physiology of the stem cells by the
aid of viral vectors (Sawada et al. 2006). Alternatively,
(stem) cell rejuvenation has been shown after culturing
in a hypoxic environment (Barros et al. 2013; Leontieva
et al. 2012; Malladi et al. 2007), a condition influencing
cell proliferation and fate (Malladi et al. 2007;
Mohyeldin et al. 2010), although hypoxia was also
found to induce apoptosis in bone marrow-derived
hMSCs (Zhu et al. 2006).
In the present work, we analyzed the effect of TO-
RGN treatment on hADSC senescence in vitro, and
demonstrated that this physical treatment, without the
aid of viral vectors, was able to counteract biochemi-
cal and morphological changes occurring in stem cells
during aging. Such a conclusion could be inferred
from a number of interrelated observations, including
(1) the effectiveness of TO-RGN to decrease both the
number of SA-β-Gal-positive cells and their staining
intensity, (2) the ability of TO-RGN-treated cells to
retain the typical fibroblast-like morphology of
hADSCs, with respect to the enlarged shape acquired
by unexposed cells through prolonged culturing, (3) the
remarkable preservation of the multilineage differentiat-
ing potential observed in TO-RGN exposed hADSCs
that even at late passages retained their adipogenic, os-
teogenic, and vasculogenic potential, as compared with
the multipotency decline found in aged, unexposed cells.
It is now evident that senescence is also regulated
by specific mediator genes, accumulating during the
cell life span, including p16INK4, ARF, p53, and
p21CIP1. In particular, p16INK4 and ARF inhibit
the activity of cyclin-dependent kinase 4 and 6, essen-
tial for the G1 progression through the cell cycle,
while p53 regulates the expression of p21 CIP1, which
inhibits cyclin-dependent kinase2, a regulator of the S
phase progression (Zou et al. 2002).
Our observation that TO-RGN exposure was also
effective in counteracting the progressive upregulation
of these genes occurring throughout multiple passages
in culture supports future clinical application of REAC
technology as a potential tool for blunting age-related
degenerative diseases.
Further studies are in progress to investigate wheth-
er the TO-RGN treatment may also interact with the
multifaceted signal patterning through which hypoxia
determines the cell state and inhibits geroconversion
(Leontieva et al. 2012).
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